This Week in Cardiology May 16 2025 This Week in Cardiology
15 snips
May 16, 2025 Explore groundbreaking findings on blood pressure medication timing, revealing that when you take them may not matter as much as once thought. Discover the competitive edge of tirzepatide over semaglutide in promoting weight loss and improving cardiometabolic health. Delve into age-specific troponin reference limits, particularly relevant for older patients. Plus, learn about genetic factors in athletes and the rapid titration benefits for heart failure treatments, highlighted by recent clinical trials.
AI Snips
Chapters
Transcript
Episode notes
Timing of BP Meds Does Not Matter
- Two large, independent trials found no benefit from taking blood pressure meds at night instead of morning.
- The positive results from the earlier Spanish Hygia trial are likely implausible and disproven by these newer studies.
Tirzepatide Outperforms Semaglutide
- Tirzepatide, a dual GIP and GLP-1 agonist, causes significantly more weight loss than semaglutide in obese non-diabetic patients.
- Cardiometabolic risk factors like blood pressure and glucose improve more with tirzepatide but cardiovascular outcome trials are ongoing.
Age-Specific Troponin Reference Limits
- Current troponin reference limits do not account for age differences, leading to frequent mild elevations in older adults.
- Using age-specific troponin upper reference limits could reduce unnecessary downstream testing and better reflect true myocardial injury.